Estrogen receptor alpha (ESR1) gene amplification is frequent in breast cancer

被引:288
作者
Holst, Frederik
Stahl, Phillip R.
Ruiz, Christian
Hellwinkel, Olaf
Jehan, Zeenath
Wendland, Marc
Lebeau, Annette
Terracciano, Luigi
Al-Kuraya, Khawla
Jaenicke, Fritz
Sauter, Guido
Simon, Ronald [1 ]
机构
[1] Univ Med Ctr Hamburg Eppendorf, Dept Pathol, D-20246 Hamburg, Germany
[2] Univ Basel Hosp, Dept Pathol, CH-4031 Basel, Switzerland
[3] Univ Med Ctr Hamburg Eppendorf, Dept Urol, D-20246 Hamburg, Germany
[4] Univ Med Ctr Hamburg Eppendorf, Dept Gynecol, D-20246 Hamburg, Germany
[5] King Faisal Specialist Hosp & Res Ctr, Riyadh 21211, Saudi Arabia
关键词
D O I
10.1038/ng2006
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Using an Affymetrix 10K SNP array to screen for gene copy number changes in breast cancer, we detected a single-gene amplification of the ESR1 gene, which encodes estrogen receptor alpha, at 6q25. A subsequent tissue microarray analysis of more than 2,000 clinical breast cancer samples showed ESR1 amplification in 20.6% of breast cancers. Ninety-nine percent of tumors with ESR1 amplification showed estrogen receptor protein overexpression, compared with 66.6% cancers without ESR1 amplification ( P < 0.0001). In 175 women who had received adjuvant tamoxifen monotherapy, survival was significantly longer for women with cancer with ESR1 amplification than for women with estrogen receptor - expressing cancers without ESR1 amplification ( P = 0.023). Notably, we also found ESR1 amplification in benign and precancerous breast diseases, suggesting that ESR1 amplification may be a common mechanism in proliferative breast disease and a very early genetic alteration in a large subset of breast cancers.
引用
收藏
页码:655 / 660
页数:6
相关论文
共 26 条
  • [11] Koivisto P, 1997, CANCER RES, V57, P314
  • [12] Nessling M, 2005, CANCER RES, V65, P439
  • [13] Pauletti G, 1996, ONCOGENE, V13, P63
  • [14] Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment
    Pegram, MD
    Lipton, A
    Hayes, DF
    Weber, BL
    Baselga, JM
    Tripathy, D
    Baly, D
    Baughman, SA
    Twaddell, T
    Glaspy, JA
    Slamon, DJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) : 2659 - 2671
  • [15] Diagnostic evaluation of HER-2 as a molecular target: An assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials
    Press, MF
    Sauter, G
    Bernstein, L
    Villalobos, IE
    Mirlacher, M
    Zhou, JY
    Wardeh, R
    Li, YT
    Guzman, R
    Ma, YL
    Sullivan-Halley, J
    Santiago, A
    Park, JM
    Riva, A
    Slamon, DJ
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (18) : 6598 - 6607
  • [16] Rose C, 1980, Recent Results Cancer Res, V71, P134
  • [17] Tissue microarrays for comparing molecular features with proliferation activity in breast cancer
    Ruiz, C
    Seibt, S
    Al Kuraya, K
    Siraj, AK
    Mirlacher, M
    Schraml, P
    Maurer, R
    Spichtin, H
    Torhorst, J
    Popovska, S
    Simon, R
    Sauter, G
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2006, 118 (09) : 2190 - 2194
  • [18] SAUTER G, 1993, CANCER RES, V53, P2199
  • [19] HETEROGENEITY OF CHROMOSOME-17 AND ERBB-2 GENE COPY NUMBER IN PRIMARY AND METASTATIC BLADDER-CANCER
    SAUTER, G
    MOCH, H
    GASSER, TC
    MIHATSCH, MJ
    WALDMAN, FM
    [J]. CYTOMETRY, 1995, 21 (01): : 40 - 46
  • [20] Shoker BS, 1999, J PATHOL, V188, P237